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Purpose: Oxidative phosphorylation is under dual genetic control of the nuclear and the mitochondrial DNA
(mtDNA). Oxidative phosphorylation disorders are clinically and genetically heterogeneous, which makes it difficult
to determine the genetic defect, and symptom-based protocols which link clinical symptoms directly to a specific
gene or mtDNA mutation are falling short. Moreover, approximately 25% of the pediatric patients with oxidative
phosphorylation disorders is estimated to have mutations in the mtDNA and a standard screening approach for
common mutations and deletions will only explain part of these cases. Therefore, we tested a new CHIP-based
screening method for the mtDNA. Methods: MitoChip (Affymetrix) resequencing was performed on three test
samples and on 28 patient samples. Results: Call rates were 94% on average and heteroplasmy detection levels
varied from 5–50%. A genetic diagnosis can be made in almost one-quarter of the patients at a potential output
of 8 complete mtDNA sequences every 4 days. Moreover, a number of potentially pathogenic unclassified variants
(UV) were detected. Conclusions: The availability of long-range PCR protocols and the predominance of single
nucleotide substitutions in the mtDNA make the resequencing CHIP a very fast and reliable method to screen the
complete mtDNA for mutations. Genet Med 2006:8(10):620–627.
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Oxidative phosphorylation (OXPHOS) disorders affect at
least 1 in 8,000 of the general population and belong to the
group of most common inherited metabolic diseases.1 Disease
manifestations due to OXPHOS defects can be highly variable,
but usually involve tissues with a high energy demand like
heart, muscle, renal and the endocrine systems.2 Several well-
described syndromes are known, like Kearns-Sayre (KSS) and
Pearson syndrome, Neuropathy Ataxia Retinitis Pigmentosa
(NARP), Mitochondrial Encephalomyopathy, Lactic Acidosis
and Stroke-like episodes (MELAS) and Myoclonus Epilepsy
and Ragged Red Fibers (MERRF). However, OXPHOS defects
can also manifest with more common and less specific symp-
toms, like type 2 diabetes, deafness, encephalopathy, myop-
athy, and cardiomyopathy. OXPHOS disorders therefore
cause significant morbidity and mortality and have a broad
impact on public health.
Approximately 25% of the pediatric patients with OXPHOS
disorders havemutations in themtDNA, but these are difficult
to find due to the genetic and clinical heterogeneity.3 As the
number of mtDNA mutations has increased to over 250 and
the clinical specificity lags behind, symptom-based protocols
fall short and screening of the entiremtDNA is preferable.4 The
recently introduced MitoChip (Affymetrix) is a new method
for mtDNA resequencing.5,6 In this paper we describe our ex-
perience of the complete mtDNA screening of 28 patients with
OXPHOS disease by MitoChip resequencing.
MATERIALS AND METHODS
Patient and test samples
Genomic DNA was isolated from muscle according to the
protocol of Mullenbach et al.7 DNA from 3 conventionally se-
quenced patients, a patient with a heteroplasmic 5 bp deletion,8
and 28 patients with a clinical and/or biochemical phenotype of
OXPHOS disease were analyzed on the MitoChip. These pa-
tients were all negative for the MELAS m.3243AG, MERRF
m.8344AG,andNARPm.8993TC/Gmutations, and for large
deletions of the mtDNA.
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MitoChip and experimental procedure
The MitoChip contains both sense and antisense probes
specific for the forward and reverse sequence of two fragments
of the mtDNA. One fragment interrogates 15,446 bases of the
mtDNA minus the D-loop sequence. The other fragment is a
duplicate of the first fragment, comprising 12,938 bases of the
mtDNA coding sequence minus the sequence of the 12S and
16S mitochondrial ribosomal RNA genes. The two fragments
are separated on the chip by a control fragment (Affymetrix).
Oligonucleotide probes are synthesized in situ on the chip by
Affymetrix by standard photolithography and solid-phase
DNA synthesis.9,10 For each position of themtDNA fragments,
four 25-mer probes are represented on the chip, each with a
different nucleotide in the middle (A, G, C, or T) allowing for
the detection of all possible nucleotide substitutions. The
probe with the correct corresponding nucleotide in themiddle
for each mtDNA position will give the highest signal intensity
after hybridization and scanning. The entire mtDNA was am-
plified using the Expand Long Template system (Roche) in 2
fragments (A andB) of 8,466 bp and 7,866 bp in length, with an
overlap of 235 bp. The primers for fragment A were forward
primer [5=-ccgcttctggccacagcacttaaacacatc-3=] and reverse
primer [5=-aggaggttagttgtggcaat-3=], and for fragment B for-
ward primer [5=-gcttcattcattgcccccac-3=] and reverse primer
[5=-ggaggatggtggtcaagggacccctatctg-3=]. The 7.5-kb control se-
quence was amplified using the primers and template from the
Customseq™ control kit (Affymetrix). PCR products were pu-
rified using the QIAQuick PCR cleanup kit (QIAGEN).
Equimolar amounts of the amplified fragments A and B were
pooled and fragmented together with the amplified 7.5-kb
control sequence, labeled and hybridized on a pre-hybridized
MitoChip as described in the Affymetrix CustomSeq Rese-
quencing protocol. Chips were washed and stained on the
GeneChip fluidics station 400 (Affymetrix) using the pre-
programmed CustumSeq Resequencing wash and stain pro-
tocol (DNA ARRAY-WS2). The MitoChips were scanned
using the Affymetrix GeneChip scanner 3000 creating.CEL
files for subsequent analysis.
Data analysis
Affymetrix GeneChip DNA Analysis Software (GDAS) ver-
sion 3.0.1.3 beta was used to analyze the .CEL files, using the
default program settings. A report file was created by GDAS
listing the nucleotide variations for both chip fragments com-
pared to the Revised Cambridge Reference Sequence
(RCRS).4,11 Discrepancies between nucleotide calls for both
chip fragments were evaluated manually. The final base
changes were written to a text file (“affy output file”). A second
analysis was performed using R, a free software environment
for statistical computing and graphics.12 In the R analysis, each
chip (.CEL file) was analyzed separately. For each position the
nucleotide with the highest signal intensity was determined,
not taking into account the background signal. Nucleotide
changes were printed to a text file (“R output file”). Finally the
“affy output files” and the “R output files” were compared and
combined, resulting in a list of variations for each sample. Dis-
crepancies between the GDAS and R output were evaluated
manually by directly looking at the chip image or by conven-
tional sequencing. Unless otherwise mentioned, throughout
this paper the phrase “MitoChip analysis” refers to the com-
bined GDAS and R analysis.
Validation of variations and heteroplasmy levels
Both strands of a fragment carrying a variant were cycle
sequenced using the BigDye Terminator v3.1 Cycle sequencing
kit, an ABI-PRISM 3100 genetic analyser and the Sequence
Analysis 3.7 software package. The level of heteroplasmy was
determined bymutation specific restriction digestion. In case a
restriction site was gained or lost, fragments were amplified
using primers surrounding the underlying variation, otherwise
a specific mismatch primer was designed in order to create a
restriction site. On PCR amplification, a labeled primer was
added to the reaction in the last PCR cycle to label the PCR
products. Labeled PCR products were digested and the frag-
ments were analyzed on an ABI-PRISM 3100 genetic analyser
using the GeneScan Analysis 3.7 software package (Applied
Biosystems). The level of heteroplasmy was determined by cal-
culating the ratio of the mutant or wild type peak area (de-
pending on the gain or loss of a restriction site by the nucleo-
tide variation) and the sum of the mutant and wild type peak
areas. Primer sequences and reaction conditions are available
on request.
RESULTS
MitoChip performance and validation
Based on a total of 32 DNA samples, the average GDAS call
rate was 94.0%, ranging from 88.9–96.8%. Of the GDAS “no
call” signals, 0.72% (212/29,366) of the chip positions gave a
“no call” for each of the 32 chips analyzed, corresponding to
134 mtDNA nucleotide positions. A GDAS call was always
given for each of the 32 chips for 12200 mtDNA nucleotide
position (20,486 out of 29,366 (70%) chip positions). For 7
CHIPs GDAS and R analysis were compared for the entire
sequence and R analysis accounted for an average of 24.2%
(ranging from 13–37%) of the total amount of base changes in
the output files. Five unclassified variants (UVs) were identi-
fied by the R analysis, which were not detected by the standard
GDAS analysis. For the three test samples, which were also
sequenced conventionally, 34/35 (97%) variations were called
correctly on the MitoChip. In two test samples, one and six
variations were additionally detected by the MitoChip. By re-
interpretation of the conventional sequencing results, one of
the variations which were detected additionally by the Mito-
Chip proved to be a low percentage heteroplasmic substitution
(false negative), and the other additional variants appeared to
be falsely detected as a nucleotide variant by the MitoChip
(false positives). A known 5-bp deletion was also tested, but
not detected. Two DNA samples differing at 16 positions in
their mtDNA sequence were mixed at ratios of 1:1, 1:9, and
1:19. In the mix sample analyses (only GDAS), the Total Qual-
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ity Threshold Score setting was set at 30 and 75. Fifteen of 16
positions were called correctly at a heteroplasmy level of 50%
for both TQT settings. Only one position was called correctly
as heteroplasmic in all threemix samples at both TQT settings.
At a TQT value of 30, “no call” signals were 3 times more often
observed at the 16 investigated heteroplasmy positions than at
a TQT value of 75.
mtDNA variations in 28 patients
A total of 520 variations were detected in 28 patients, com-
prising 197 unique nucleotide substitutions. Fifteen hetero-
plasmic variations were detected in a total of 11 patients. Four
of these variations were confirmed by sequencing and muta-
tion specific restriction digestion (m.15939CT at 7%,
m.13513GA at 14%,m.3243AT at 34%, andm.13042GA
at 84%); two proved to be homoplasmic single base pair inser-
tions (m.3229_3230insA and m.3158_3159insT); two ap-
peared to be false positive; onewas shown to be a homoplasmic
polymorphism (m.15452CA); the remaining six were not
tested because they were considered not to be pathogenic. Of
all detected variations, three were known pathogenic muta-
tions (Table 1), 114 have been reported before as polymor-
phisms (Supplementary Table 1), 41 did not result in an amino
acid change and were most likely polymorphisms (Supple-
mentary Table 1), and 39 were unclassified variants (UVs),
some of which were likely pathogenic (Table 2). Eight vari-
ants were located in tRNAmolecules (Fig. 1). In three patients
known pathogenic mutations were detected and in 23 patients
UVs were detected. In five patients only polymorphisms were
detected.
UVswere evaluated for evolutionary conservation, for func-
tional significance by determining the effect on the tRNAor on
the protein, and, when available, for segregation in the family.
Seven UVs were located in six tRNA genes (Fig. 1), 11 UVs in
the 12S and 16S rRNA genes, one UV in themtDNA transcrip-
tion terminator site, and 20UVs in the protein encoding genes.
Of the eight tRNA variations (Fig. 1), the m.15939CT varia-
tion in the tRNA-Thr gene was heteroplasmic with a mutation
load of 7%. The other tRNA variations were all homoplasmic
or close to homoplasmy (98% mutation load). Two of the
variations in the protein encoding genes were heteroplasmic
84% and 70%, respectively, for the m.13042GA in the ND5
gene and m.14258GA in the ND6 gene.
Single nucleotide insertions were detected as well. A hetero-
plasmic m.3158AT transition on the CHIP proved to be a
single nucleotide insertion (m.3158_3159insT) by standard se-
quencing. Additionally, the homoplasmic m.3229_3230insA
insertion was initially detected by the MitoChip analysis as a
heteroplasmic m.3229TA transition.
Table 1
Pathogenic mutations
Position nt change aa change Mutation loada Locus Diseaseb
Number of
samples aa/nt Conservationc
No. patients
previously
described Reference(s)
Evident pathogenic mutations
3243 AT – 34% tRNA-Leu1 MM 1 30/31 species 1 Shaag et al.
(1997)19
3697 GA G-S 97% ND1 MELAS 1 Hs/Pt/Cf/Mm/Rn/
Gg/Dm/Ag/Ce/
At/Os
1 Kirby et al.
(2004)21
13513 GA D-N 13–15% ND5 MELAS/Leigh
Disease
1 Hs/Pt/Cf/Mm/Rn/
Gg/Dm/Ag/Ce/
At/Os
1 Santorelli et al.
(1997)26
4 Pulkes et al.
(1999)23
1 Penisson-
Besnier et al.
(2000)28
3 Chol et al.
(2003)27
3 Kirby et al.
(2003)25
6 Sudo et al.
(2004)24
aMutation loads are determined by mutation specific restriction digestion analysis followed by GeneScan analysis.
bMM, Mitochondrial Myopathy; MELAS, Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes.
cFor the tRNA variations, the nucleotide conservation is shown. For the variations in protein encoding genes, the amino acid conservation is displayed.
Hs,Homo sapiens; Pt, Pan troglodytes; Cf, Canis familiaris; Mm,Mus musculus; Rn, Rattus norvegicus; Gg, Gallus gallus; Dm,Drosophila melanogaster; Ag, Anopheles
gambiae; Ce, Caenorhabditis elegans; At, Arabidopsis thaliana; Os, Oryza sativa.
tRNA conservations were taken from the website dealing with the compilation of mammalian tRNA genes (http://mamit-trna.u-strasbg.fr/index.html).32
van Eijsden et al.
622 Genetics IN Medicine
Table 2
Unclassified variants
Position nt change aa change Mutation loada Locus No. of samples nt Conservationd Pathogenicity scoree
Non-protein-coding region, unclassified variants
892 AT – h 12S rRNA 3 –
1860 AG – 100%b 16S rRNA 1 –
2098 GA – 100% and 16S rRNA 1 –
2259 CT – 100%b 16S rRNA 1 –
2361 GA – 100%b 16S rRNA 1 –
2581 AG – 100%b 16S rRNA 1 –
2757 AG – 100%b 16S rRNA 1 –
2768 AG – 100%b 16S rRNA 2 –
2825 GC – h 16S rRNA 4 –
3105 AG – 100%b 16S rRNA 1 –
3159 insT – 100%b 16S rRNA 1 –
3229 insA – h Transcription
terminator
1 –
4336 TC – 98% tRNA-Gln 2 13/31 species
5558 AG – 100% tRNA-Trp 1 31/31 species
5592 AG – 100% tRNA-Ala 1 28/31 species
5850 TC – 98% tRNA-Tyr 1 30/31 species
12308 AG – 100%b tRNA-Leu2 5 31/31 species
15890 CT – 100% tRNA-Thr 1 31/31 species
15939 CT – 7% tRNA-Thr 1 13/31 species
Protein-coding region, unclassified variants
3308 TC MT 100%b ND1 2 Hs/Cf/Mm/Rn/Ag 0 (28)
4501 CT SF 100%b ND2 1 Hs/Cf 0 (20)
4561 TC VA 100%b ND2 1 Hs/Pt/Mm/Rn/At/Os 0 (20)
5319 AG TA 100%b ND2 1 Hs 0 (20)
6408 AG IV 100%b CO1 1 Hs/Pt/Cf/Mm/Rn/Gg/Dm/Ag/Sp 6 (20)
7146 AG TA 100%b CO1 2 Hs/Cf 0 (28)
7389 TC YH 100%b CO1 2 Hs/Pt 0 (28)
8516 TC WR 100%b ATP8 1 Hs/Pt/Mm/Rn 7 (23)
8975 TC LP 100%b ATP6 1 Hs/Pt/Gg 4 (20)
10680 GA AT 100%b ND4L 1 Hs/Pt/Cf/Mm/Rn 15 (28)
11447 GA VM 100%b ND4 1 Hs/Pt/Cf 2 (20)
13042 GA AT 84% ND5 1 Hs/Pt/Cf/Mm/Rn/Gg/Dm/Ag/Ce/At/Os 18 (31)
13630 AG TA 100%b ND5 1 Hs/Pt/Gg/Dm/Ag 8 (28)
13880 CA SY 100%b ND5 2 Hs/Pt/At 0 (28)
14207 GA TI 100%b ND6 1 Hs/Pt/Cf 8 (28)
14258 GA PL 70%c ND6 1 Hs/Pt 5 (20)
14766 CT TI 100%b CYB 13 Hs/Pt 8 (28)
15311 AG IV 100%b CYB 1 Hs/Pt/Cf/Mm/Rn/Gg/Ag/Ce/Sp/Sc/Kl/Eg 1 (23)
15725 CT LF 100%b CYB 1 Hs/Pt/Cf/Gg/Kl/Eg/At 2 (20)
15824 AG TA 100%b CYB 1 Hs/Pt/Cf/Gg 0 (20)
aMutation loads are determined by mutation specific restriction digestion analysis followed by GeneScan analysis.
bMutations load estimated by MitoChip and/or sequencing results only.
cAlso confirmed with denaturing high-performance liquid chromatography (dHPLC) analysis.
dAg,Anopheles gambiae; At,Arabidopsis thaliana; Ce,Caenorhabditis elegans; Cf,Canis familiaris; Dm,Drosophilamelanogaster; Eg, Eremothecium gossypii; Gg,Gallus
gallus; Hs, Homo sapiens; Kl, Kluyveromyces lactis; Mm,Mus musculus; Os, Oryza sativa; Pt, Pan troglodytes; Rn, Rattus norvegicus; Sc, Saccharomyces cerevisiae; Sp,
Schizosaccharomyces pombe.
eThe pathogenicity score is calculated according to the criteria set byMitchell et al.22 Since information was not available on all criteria, themaximal score using only
the available information is indicated between brackets.
hDetected as heteroplasmic by MitoChip analysis.
tRNA conservations were taken from the website dealing with the compilation of mammalian tRNA genes (http://mamit-trna.u-strasbg.fr/index.html).32
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DISCUSSION
MitoChip performance and validation
MitoChip resequencing is a very rapid method to screen the
mtDNA for mutations. Eight samples can be analyzed by one
technician over a period of 4 days. The average call rate of
94.0% is within the range described by Affymetrix and others.5
The additional R analysis led to an increase in total base calls
and to the identification of 5 UVs (4/7 samples), which would
have been missed by GDAS analysis only. Of the 212 chip po-
sitions (0.72%) (134mtDNAnucleotide positions) which con-
sistently gave a “no call,” 197 (124 mtDNA nucleotide posi-
tions) were cytosine nucleotides. Previously, it was reported
that 1.7% of the bases always gave a “no call” in a dataset of 26
chips.5 About 51% of these were from regions containing two
or more successive C bases. R-analysis showed that in these re-
gions especially the forward strand differed from the reference
sequence, whereas the reverse sequence gave a call equal to the
reference sequence. The reason for this is yet unknown. The
Fig. 1. Eight tRNA variations (unclassified variants and mutations) detected in 28 patients with OXPHOS disease. Detected were an m.3243AT variation in the tRNA-Leu1, an
m.4336TCvariation in the tRNA-Gln gene, anm.5558AGvariation in the tRNA-Trp gene, anm.5592AGvariation in tRNA-Ala gene, anm.5850TCvariation in the tRNA-Tyr gene,
anm.12308AGvariation in the tRNA-Leu2 gene, and anm.15890CT variation andm.15939CT variation in the tRNA-Thr gene. The images are adapted from thewebsite dealing with
the compilation of mammalian tRNA genes (http://mamit-trna.u-strasbg.fr/index.html).32
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mtDNA nucleotide positions of twelve common mtDNAmuta-
tions (m.1555AG, m.3243AG, m.3460GA, m.8344AG,
m.8993TG/C. m.9176TC, m.10159TC, m.11778GA,
m.13513GA, m.14459GA, m.14484TC, and m.14487TC),
were not among the nucleotide positions always giving a “no-
call.” Within-chip and between-chip reproducibility have al-
ready been determined showing a within-chip error rate of
0.0025%and a between-chip error rate of 0.0027%, illustrating
that the base calls were reproducible for 99.99%.5 In our
experiments 97% of the variations were called correctly in
three previously sequenced samples, which is comparable with
the 95% reported before in 18 samples.5 In the three test sam-
ples, only six variations appeared be false positive after fol-
low-up investigation. It is unlikely that PCR errors are caus-
ative for false positive MitoChip calls since there is a large
number of templates for the PCR, and the heteroplasmy levels
due to sporadic PCR errorswill be below the detection limit. As
GeneChip Resequencing Arrays only support detection of ho-
mozygous and heterozygous single nucleotide substitutions,
small deletions (5 bp) could not be detected, although 2 single
nucleotide insertions were detected as heteroplasmic “sub-
stitutions.” One might expect that the heteroplasmic 5-bp
deletion would be detected by the MitoChip as a loss of signal,
but available software is insufficient for these quantitative
analyses, especially if over 50% of the wild type mtDNA is still
present.8
Although the GDAS software was designed to detect ho-
mozygous (homoplasmic) and heterozygous (50% hetero-
plasmy) single base pair substitutions only, it was previously
shown that heteroplasmic variations at levels as low as 2%were
detectable.5 However, in our dilution experiments only one
out of 16 positions could be identified correctly as a heteroplas-
mic variation in the 5%, 10%, and 50%mix samples. Notably,
the number of “no calls” at these 16 heteroplasmic positions
was three times higher at theTQT setting of 30 compared to the
GDAS default TQT setting of 75, illustrating a difficulty for the
algorithm to assign a call for the particular position, probably
because of the signal of the heteroplasmic variant. This sug-
gests that further development of the data analysis algorithm
and tuning of the data analysis settings can improve the detec-
tion level of heteroplasmic mutations. An option would be to
customize ourR-analysis tomake it sensitive for heteroplasmic
variations. Nevertheless, we were able to detect a heteroplas-
mic variation in the tRNA-Thr gene (m.15939CT) in a pa-
tient with a mutation load as low as 7%. Additionally, a patho-
genic mutation in the ND5 gene (m.13513GA) was identified
and validated at a heteroplasmic level of 13–15%. Apparently the
sensitivity forheteroplasmydetection is differentperposition and
probably depends on the sequence surrounding the variation.
MitoChip compared to other methods
Resequencing Chips are powerful if long-range PCR proto-
cols are available and substitutions are the predominant patho-
genic mutations, which is the case for the mtDNA. Other
methods for mtDNA mutation analysis are conventional se-
quence analysis, single strand conformation polymorphism
(SSCP) analysis, denaturing gradient gel electrophoresis
(DGGE), temperature gradient gel electrophoresis (TGGE),
denaturant capillary electrophoresis (DCE) and denaturing
high-performance liquid chromatography (dHPLC).13–17
These techniques all have their advantages and disadvantages
with respect to costs time consumption, high-output possibil-
ities, heteroplasmic detection limit, and type of mutations that
can be detected (Table 3). At thismoment, heteroduplex-based
methods (dHPLC, DGGE, TGGE, and DCE) appear to be
more sensitive than the MitoChip for heteroplasmy detection,
with detection sensitivities as low as 0.5%.14–16,18 SSCP and
conventional sequence analysis are not able to detect low per-
centages of heteroplasmy. MitoChip resequencing is able to
detect heteroplasmic variants at low levels, although the data
analysis needs to be optimized to reach similar detection levels.
Although the costs per nucleotide are cheaper for conventional
sequencing,5 considering the overall costs per sample, Mito-
Chip resequencing is preferable over conventional sequencing,
mostly due to a tremendous gain in labor costs (8 samples can
be analyzed by one technician over a period of 4 days) and
automated analysis at comparable bench costs.
MtDNA variations in 28 clinical samples
The pathogenic m.3243AT mutation was found in a pa-
tient with proximal myopathy, ptosis and ophthalmoplegia at
a mutation level of 34%. Magnetic resonance imaging (MRI)
of the brain showed white matter abnormalities and muscle
creatine phosphokinase levels were elevated. Muscle biopsy
histomorphology revealed ragged red fibers (RRF) and cyto-
chrome c oxidase (COX) negative fibers. This mutation has
been previously described in muscle (81.4%), skin (69.3%)
and blood (13.8%) of a 9-year-old girl with muscle weakness,
encephalopathy and a reduction of the activity of OXPHOS
complexes I, III and IV.19 The mutation is located at the same
position as the classicalMELASm.A3243AGmutation at the
first position of the D-loop in the tRNA-Leu1 molecule (Fig.
1), leading to a dramatic loss of aminocylation efficiency.
Moreover, residue A14 of this tRNA is strongly conserved
Table 3
Comparision of mtDNA mutation screening methods
SSCP DGGE TGGE DCE dHPLC Sequencing MitoChip
Equipment
costs
low low low high high high high
Labor
intensive
yes yes yes no no yes no
High-output       
Heteroplasmy
detection
      ()
Homoplasmy
detection
      
SSCP, single strand conformation polymorphism;DGGE, denaturing gradient
gel electrophoresis; TGGE, temperature gradient gel electrophoresis; DCE,
denaturant capillary electrophoresis; dHPLC, denaturing high-performance
liquid chromatography.
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within all classical tRNA molecules and it is involved in estab-
lishing tertiary interactions with other residues of the tRNA.20
The pathogenic m.3697GA mutation in the ND1 gene was
detected at a mutation load higher than 97% in a patient with
spastic dystonia, elevated levels of lactate and pyruvate in blood
serum and cerebrospinal fluid. The affected amino acid is evolu-
tionary highly conserved (Table 1) and the mutation has been
described before in a MELAS patient with 80% of the
m.3697GA mutation in muscle and 79% in skin fibroblasts.21
Pathogenicity of the mutation was confirmed by fusion experi-
mentswith0 cell lines (norestorationof complex I activity) com-
bined with blue native polyacrylamide gel electrophoresis (BN-
PAGE) (low levels of fully assembled complex I).21 The
m.3697GAmutations was also evaluated according to the scor-
ing system to assess pathogenicity of complex Imutations.22 This
score can range from0 (not pathogenic) to 40 (pathogenic) and is
based on several criteria: biochemical defect, functional studies,
reports by two or more independent laboratories, heteroplasmy,
segregation in the family, and evolutionary conservation. The
m.3697GA mutation reached a score of 32. Our report of this
mutation as a second independent laboratory will increase the
score to 37 points, which is above the “pathogenic” cutoff of 30.
The m.13513AG mutation was detected in a patient with en-
cephalopathy, strokes, dystonia, signs of Parkinsonism, mental
retardation and signs of early fatigued. Biochemical analysis indi-
cated a deficiency of the pyruvate dehydrogenase complex
(PDHC) in muscle. The m.13513AG transition in the ND5
gene changes an amino acid strongly conserved over 11 species
(Table 1) and has been related toMELAS and Leigh syndrome in
several reports.23–28 The pathogenicity score for this mutation is
39.22 The functional importance of this amino acid is further sup-
ported by the finding of a pathogenic mutation m.13514AG,
affecting the same codon, that results in a different amino acid
replacement (D393G vs. D393N) in twoMELAS patients.29
UVs were evaluated with respect to heteroplasmy, evolu-
tionary conservation, functional influence of the effect on
tRNA or protein, and segregation in the family.22,30,31 Several
UVs were likely to be pathogenic, but the effect of others is still
unclear. The m.5850TC variation had a mutation load of
98% inmuscle and 13% in urine, but it could not be detected
in blood or hair of the patient. It was not present in blood, hair,
or urine from the patient’s clinically unaffected mother,
brother, and sister.Thepositionof this variation in the tRNA-Tyr
gene is evolutionaryhighly conserved.Thesedata strongly suggest
a pathogenic role. A second variation with a high probability of
pathogenicitywas the homoplasmicm.3229-3230insA. This vari-
ation is located in the transcription terminator site and may
disturb the function of this site. Moreover, the location of this
variationbeingexactlybetweenthe16SrRNAgeneandthe tRNA-
Leu1 genemight result in a faulty cleavage of the RNA after tran-
scription.A faulty cleavage could have consequences for the func-
tion of the tRNA-Leu1 and 16S rRNA genes. The m.13042GA
variation in the ND5 gene was heteroplasmic (84%) and the in-
volved amino acid was also strongly conserved (Table 2), which
favors a pathogenic role. Them.14258GA variation in theND6
genewas also aheteroplasmic (70%)variation in aprotein coding
gene.Although this variation is heteroplasmic, the affected amino
acid is not well conserved. The m.15939CT variation in the
tRNA-Thrgenewasalsoheteroplasmic (7%) in thepatient’smus-
cle. The variation is located in the T-loop of the tRNA molecule
and not involved in establishing tertiary interactions in the tRNA
molecule, making a pathogenic role less likely. The other ho-
moplasmic variations (Table 2) have to be further evaluated, as it
is difficult to determine pathogenicity solely based on criteria like
heteroplasmy and conservation alone. Functional and family
studies will be performed to provide the definite evidence.
Resequencing does not only detect known pathogenic mu-
tations or polymorphisms, but also UVs and risk factors for
unrelated pathology, like cancer, Alzheimer’s disease or Par-
kinson’s disease. As the significance of this latter group of vari-
ations for individual cases and their families is yet unclear and
the risk factors can not explain the primary pathology, it is
evident that these data have to be carefully dealt with by the
clinicians. Patients should be counseled about the uncertain-
ties of some of the observations and the difficulties to interpret
part of the results. However, this is inevitable and does not
counterweight the genetic diagnoses made. It will also be a
temporary problem, as due to the joint sequencing efforts
more and more information will become available about neu-
tral polymorphisms, genuine risk factors of disease, and actual
pathogenic mutations.
CONCLUSION
MitoChip resequencing is a fast, cost-effective and reliable
method with high-output capabilities for complete mtDNA
screening. A quarter of the patients with OXPHOS disease can
be genetically diagnosed by this technique, based on the detec-
tion of three pathogenic and three or four likely pathogenic
mutations in 28 patients, which confirms the percentage pre-
viously described.3 Because of the growing number of mtDNA
mutations combined with the increasing clinical heterogene-
ity, MitoChip resequencing is the preferred method to screen
the mtDNA for mutations, especially when symptom specific
screening and screening of only the most common mtDNA
mutations falls short.
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